Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript

Core Points - Hansa Biopharma hosted a virtual KOL event to discuss recent Phase III trial data [2] - The event featured distinguished guests, including Professor Montgomery and Professor Cooper, who shared their insights [2] Agenda Overview - The presentation was structured to last approximately 15 minutes, followed by a 25-minute discussion with guests and a Q&A session [3]